217 related articles for article (PubMed ID: 25957957)
1. Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
van Staveren MC; Opdam F; Guchelaar HJ; van Kuilenburg AB; Maring JG; Gelderblom H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):47-52. PubMed ID: 25957957
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
[TBL] [Abstract][Full Text] [Related]
3. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.
van Staveren MC; Theeuwes-Oonk B; Guchelaar HJ; van Kuilenburg AB; Maring JG
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1611-7. PubMed ID: 21590448
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
7. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Wettergren Y; Carlsson G; Odin E; Gustavsson B
Cancer; 2012 Jun; 118(11):2935-43. PubMed ID: 22020693
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
[TBL] [Abstract][Full Text] [Related]
9. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
10. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
11. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
12. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
[TBL] [Abstract][Full Text] [Related]
13. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
14. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
[TBL] [Abstract][Full Text] [Related]
15. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
17. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
[TBL] [Abstract][Full Text] [Related]
18. The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases.
Jacobs BAW; Snoeren N; Samim M; Rosing H; de Vries N; Deenen MJ; Beijnen JH; Schellens JHM; Koopman M; van Hillegersberg R
Eur J Clin Pharmacol; 2018 Jun; 74(6):737-744. PubMed ID: 29430582
[TBL] [Abstract][Full Text] [Related]
19. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
20. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
Gamelin E; Boisdron-Celle M; Morel A
Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
